ERBB2 and prostate carcinoma: In vitro analysis shows tumour specific differences, as PTEN is likely the dominant mechanism in glioblastoma multiforme (Sano et al, 1999) and prostate cancer (Davies et al, 2002); in breast cancer, HER-2/neu is likely the upstream activator (Zhou et al, 2000).